Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds

On Oct 1, 2019, we issued an updated research report on Tandem Diabetes Care, Inc. TNDM. The company's expansion initiatives in the global markets are a major positive. However, its heavy dependence on the sales of insulin pumps and its recurring operating losses pose concerns for the stock. Tandem Diabetes currently sports a Zacks Rank #1 (Strong Buy).

Shares of the company have outperformed its industry in the past year. The stock has surged 65.5% versus the industry's 7.1% decline. Notably, the company fared well on the top-line front with better-than-expected results in second-quarter 2019.

Strength in domestic sales along with a solid rollout of the t:slim X2 Insulin Pump in the international markets bodes well for the company. The raised sales guidance for 2019 looks promising too. Also, favorable demographics in the diabetes market are expected to boost demand for Tandem Diabetes' products.

Tandem Diabetes Care, Inc. Price

Tandem Diabetes Care, Inc. price | Tandem Diabetes Care, Inc. Quote

The company is on track to launch its second-generation AID system — t:slim X2 with Control IQ — in the fourth quarter of 2019. Per Tandem Diabetes, this AID system is expected to integrate the t:slim X2 pump with the treat-to-range technology that the company licensed from TypeZero Technologies LLC besides Dexcom’s G6 sensor.

Tandem Diabetes is also working on a mobile application, currently designed to use the Bluetooth radio capability for wirelessly uploading pump data to connect, receive notification of pump alerts and alarms as well as assemble other health-related information from third-party sources.

On the flip side, excessive reliance on the sales of insulin pumps and persistent operating losses pose threats to the company. Moreover, the company's operations might be affected by a tough competitive environment.

Other Key Picks

A few other top-ranked stocks in the broader medical space are Stryker SYK, Medtronic MDT and Amedisys AMED, each holding a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Stryker’s long-term earnings growth rate is expected to be 10.04%.

Medtronic’s long-term earnings growth rate is projected at 7.32%.

Amedisys’ long-term earnings growth rate is anticipated to be 16.26%.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.